|
|
|
|
MarketVIEW: Seasonal influenza vaccines |
|
|
|
Published October 2022
Annual seasonal influenza epidemics typically affect 5-15% of the population with mainly upper respiratory tract infections.
On a global basis around 3-5 million cases of severe illness are estimated each year with an associated 290,000 - 650,000 deaths (WHO figures).
Annual influenza vaccination is the most effective method for preventing influenza virus infection and its complications, now more so during the COVID-19 pandemic.
Recommended groups for influenza vaccination are usually those most vulnerable and include the elderly, very young and those with underlying chronic diseases.
In the US, influenza vaccination recommendations now include every person >6 mos. Globally, many influenza vaccines are still of the trivalent inactivated format (TIV)
although now the US market has 100% switched to Quadrivalent (QIV) vaccines and high dose (HD), cell and adjuvanted formats. New 2022 US ACIP recommendations have now taken a preferential stance for differentiated vaccines in the >65 yrs segment.
This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation (.pdf) which forecasts the potential
commercial volume and value of seasonal influenza vaccines across 13 major individual Western and 37 emerging or rest of world (ROW) markets to 2035.
The model contains validated volume (mio doses) estimates for all recommended target groups per country based on a thorough investigation of
national recommendations and policy and detailed country-specific vaccine coverage rates. Country market values are ascertained by a pricing
methodology based upon public/private sector prices for TIVs, QIVs, high dose (HD), LAIV and other forms where the impact of discount/return is explored.
The analysis contains a detailed US forecast by product type and individual competitor including Seqirus' QIV (Flucelvax), MF-59 adjuvanted FLUAD
and the Sanofi HD (now QIV) portfolio (Fluzone-HD + Flublok).
An updated methodology is introduced to estimate the adoption of QIV products outside of the key US market looking at >10 ROW suppliers and EU potential for new Sanofi
differentiated products Supemtek and Efluelda entering the European market to challenge CSL Seqirus.
An updated analysis of the UK expanded program is included with a brand new demand by vaccine type analysis across the EU28 region.
Key late stage R&D programs are also assessed for market entry along with the new mRNA threat (ModernaTX mRNA-1010, 1011, 1012, 1020, 1030) and Pfizer (PF-07252220, PF-07852352) that have clear implications for future product strategy. New mRNA vaccines are forecasted with conservative and optimistic scenarios.
MarketVIEW: Seasonal influenza vaccines is the ultimate up-to-date guide for this significant vaccine marketplace.
THE FULL PRODUCT IS A SUMMARY PRESENTATION (>420 slides, .pdf form) + MS-FORECAST MODEL (.xls) + MS-WORKBOOK (.xls)
To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW.
For UK orders VAT will be added at 20%.
Please review the TERMS and CONDITIONS of purchase.
|
|
|
|
|
|